<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04454658</url>
  </required_header>
  <id_info>
    <org_study_id>M20-247</org_study_id>
    <secondary_id>2020-001225-32</secondary_id>
    <nct_id>NCT04454658</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis</brief_title>
  <official_title>A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body.&#xD;
      MF disturbs the body's normal production of blood cells, causing extensive scarring in the&#xD;
      bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The&#xD;
      purpose of this study is to see how safe and tolerable ABBV-744 is, when given alone, and in&#xD;
      combination with ruxolitinib or navitoclax, for adult participants with MF.&#xD;
&#xD;
      ABBV-744 is an investigational drug being developed for the treatment of MF. The study has 4&#xD;
      segments - A, B, C, and D. In Segment A, the safe dosing regimen of ABBV-744 is identified&#xD;
      and then, given alone as monotherapy. In Segment B, C, and D, combination therapies of&#xD;
      ABBV-744 with either ruxolitinib or navitoclax are given. Adult participants with a diagnosis&#xD;
      of MF will be enrolled. Around 130 participants will be enrolled in 60 sites worldwide.&#xD;
&#xD;
      In Segment A, participants will receive different doses and schedules of oral ABBV-744 tablet&#xD;
      to identify safe dosing regimen. Additional participants will be enrolled at the identified&#xD;
      monotherapy dosign regimen. In Segment B, participants will receive oral ruxolitinib and&#xD;
      ABBV-744 will be given as &quot;add-on&quot; therapy. In Segment C, participants will receive ABBV-744&#xD;
      and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib.&#xD;
      Participants will receive treatment until disease progression or the participants are not&#xD;
      able to tolerate the study drugs.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow&#xD;
      tests, checking for side effects, and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">July 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to Approximately 1 year from start of study</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Of Participants Who Achieve Spleen Volume Reduction Of 35% Or Greater (SVR35)</measure>
    <time_frame>Up To Week 24</time_frame>
    <description>Reduction in spleen volume is measured by magnetic resonance imaging (MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of ABBV-744</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of ABBV-744.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Cmax (Tmax) Of ABBV-744</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>The amount of time taken to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Concentration Versus Time Curve (AUC) Of ABBV-744</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>AUC of ABBV-744 will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2) Of ABBV-744</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Half-life of ABBV-744 will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Of ABBV-744</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Pharmacokinetic parameters will include accumulation ratio of ABBV-744.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) Of ABBV-744</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>CL/F of ABBV-744 will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume Of Distribution (Vd/F) Of ABBV-744</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Vd/F of ABBV-744 will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Of Participants With &gt;= 50% Reduction In Total Symptom Score (TSS)</measure>
    <time_frame>Week 24</time_frame>
    <description>TSS is assessed using the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0. MFSAF v4.0 measures the burden of myelofibrosis-related symptoms. The symptoms are assessed on a 11-point numeric rating scale (NRS) anchored from 0 (absent) to 10 (worst imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Week 24</time_frame>
    <description>ORR is defined as the sum of rates of partial remission (PR) or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) Of Navitoclax</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax) Of Navitoclax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Cmax (Tmax) Of Navitoclax</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>The amount of time taken to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Concentration Versus Time Curve (AUC) Of Navitoclax</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>AUC of Navitoclax will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) Of Ruxolitinib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax) Of Ruxolitinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Cmax (Tmax) Of Ruxolitinib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>The amount of time taken to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Concentration Versus Time Curve (AUC) Of Ruxolitinib</measure>
    <time_frame>Up To Week 12</time_frame>
    <description>AUC of Ruxolitinib will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Myelofibrosis (MF)</condition>
  <arm_group>
    <arm_group_label>Segment A: ABBV-744 Dose Identification and Optimization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of ABBV-744 to identify the safe dosing regimen and schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment A: ABBV-744 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the identified safe dosing regimen of ABBV-744 as monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment B: Ruxolitinib + ABBV-744 &quot;Add on&quot; Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and ABBV-744 as &quot;add-on&quot; therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment C: ABBV-744 + Navitoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have previously been exposed to JAKi, and stopped such therapy, will receive ABBV-744 and navitoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment D: ABBV-744 + Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have never received JAKi will receive ABBV-744 and ruxolitinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-744</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Segment A: ABBV-744 Dose Identification and Optimization</arm_group_label>
    <arm_group_label>Segment A: ABBV-744 Monotherapy</arm_group_label>
    <arm_group_label>Segment B: Ruxolitinib + ABBV-744 &quot;Add on&quot; Therapy</arm_group_label>
    <arm_group_label>Segment C: ABBV-744 + Navitoclax</arm_group_label>
    <arm_group_label>Segment D: ABBV-744 + Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navitoclax</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Segment C: ABBV-744 + Navitoclax</arm_group_label>
    <other_name>ABT-263</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Segment B: Ruxolitinib + ABBV-744 &quot;Add on&quot; Therapy</arm_group_label>
    <arm_group_label>Segment D: ABBV-744 + Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory values indicative of adequate bone marrow, renal, and hepatic function&#xD;
             meeting protocol criteria.&#xD;
&#xD;
          -  Completion of the Myelofibrosis System Assessment Form (MFSAF) on at least 4 out of&#xD;
             the 7 days prior to Day 1 with at least 2 symptoms with a score &gt;=3 or a total score&#xD;
             of &gt;=10.&#xD;
&#xD;
          -  Documented diagnosis of intermediate or high-risk primary myelofibrosis (PMF),&#xD;
             post-polycythemia vera MF (PPV-MF) or post-essential thrombocytopenia MF (PET-MF) as&#xD;
             defined by the World Health Organization (WHO).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          -  Intermediate - 2, or High-Risk disease as defined by the Dynamic International&#xD;
             Prognostic Scoring System (For Segment A only, Intermediate - 1 with palpable&#xD;
             splenomegaly &gt;=5 centimeters [cm] below costal margin are also eligible).&#xD;
&#xD;
          -  Splenomegaly defined as spleen palpation measurement &gt;= 5 cm below costal margin or&#xD;
             spleen volume &gt;= 450 cubic cms as assessed by Magnetic Resonance Imaging (MRI) or&#xD;
             Computed Tomography (CT) scan (for Segments A and c, baseline spleen assessment must&#xD;
             be obtained &gt; 7 days after discontinuation of most recent Myelofibrosis (MF) therapy.&#xD;
             If possible, this assessment should occur within 10 days of Cycle 1 Day 1).&#xD;
&#xD;
        Segment-Specific Prior Therapy Criteria:&#xD;
&#xD;
          -  Segment A:&#xD;
&#xD;
               -  Prior exposure to one or more Janus Kinase inhibitors (JAKi), the most recent of&#xD;
                  which was discontinued &gt; 28 days prior to Cycle 1, Day 1, and are intolerant,&#xD;
                  resistant, refractory or lost response to the JAKi.&#xD;
&#xD;
          -  Segment B:&#xD;
&#xD;
               -  Currently receiving ruxolitinib AND&#xD;
&#xD;
               -  Willingness to reduce ruxolitinib dose (if on a higher dose); and on a stable&#xD;
                  dose for 14 days or longer prior to Cycle 1 Day 1; AND&#xD;
&#xD;
               -  At least one of the following criteria (a, b, or c):&#xD;
&#xD;
                    1. &gt;= 24 weeks duration of current ruxolitinib course, with evidence of disease&#xD;
                       that is resistant, refractory, or has lost response to ruxolitinib therapy;&#xD;
&#xD;
                    2. &lt; 24 weeks duration of current ruxolitinib course with documented&#xD;
                       resistance, refractories, or loss of response, as defined by any of the&#xD;
                       following:&#xD;
&#xD;
                         -  Appearance of new splenomegaly that is palpable to at least 5 cm below&#xD;
                            the left costal margin (LCM), in participants with no evidence of&#xD;
                            splenomegaly prior to the initiation of ruxolitinib.&#xD;
&#xD;
                         -  &gt;=100% increase in the palpable distance below the LCM, in participants&#xD;
                            with measurable spleen distance 5 - 10 cm prior to the initiation of&#xD;
                            ruxolitinib.&#xD;
&#xD;
                         -  &gt;=50% increase in the palpable distance below the LCM, in participants&#xD;
                            with measurable spleen &gt; 10 cm prior to the initiation of ruxolitinib.&#xD;
&#xD;
                         -  A spleen volume increase &gt;= 25% (as assessed by MRI or CT) in&#xD;
                            participants with a spleen volume assessment available prior to the&#xD;
                            initiation of ruxolitinib.&#xD;
&#xD;
                    3. Prior treatment with ruxolitinib for &gt;= 28 days complicated by any of the&#xD;
                       following:&#xD;
&#xD;
                         -  Development of red blood cell transfusion requirement (at least 2&#xD;
                            units/month for 2 months).&#xD;
&#xD;
                         -  Grade &gt;= 3 adverse events of neutropenia and/or anemia while on&#xD;
                            ruxolitinib treatment, with improvement or resolution upon dose&#xD;
                            reduction.&#xD;
&#xD;
          -  Segment C:&#xD;
&#xD;
               -  Prior exposure to one or more JAKi (the most recent of which was discontinued &gt;&#xD;
                  28 days prior to Cycle 1 Day 1), and are intolerant, resistant, refractory or&#xD;
                  lost response to the JAKi.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Segment-Specific Prior Therapy Criteria:&#xD;
&#xD;
          -  Segment A:&#xD;
&#xD;
               -  Prior exposure to one or more Bromodomain and Extra-Terminal (BET) inhibitors.&#xD;
&#xD;
          -  Segment B:&#xD;
&#xD;
               -  Prior exposure to one or more BET inhibitors.&#xD;
&#xD;
          -  Segment C:&#xD;
&#xD;
               -  Prior exposure to one or more BET inhibitors and/or any B-Cell Lymphoma 2 (BCL-2)&#xD;
                  and/or BCL- XL inhibitor, including navitoclax.&#xD;
&#xD;
          -  Segment D:&#xD;
&#xD;
               -  Prior exposure to JAKi and/or any BET inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Davis Comprehensive Cancer Center /ID# 221790</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts - Worcester /ID# 240023</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center /ID# 224623</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center /ID# 222557</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital /ID# 221549</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College /ID# 227069</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research /ID# 222802</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma, Stephenson Cancer Center /ID# 224095</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-5418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science Univ /ID# 221801</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System /ID# 224208</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108-1597</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral /ID# 228909</name>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>1629</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires /ID# 226945</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <state>Ciuadad Autonoma De Buenos Aires</state>
        <zip>1199</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Universidade Federal de Goiás /ID# 226636</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre /ID# 226635</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 226637</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beneficencia Portuguesa de Sao Paulo /ID# 226641</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 226639</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duplicate_Hospital Israelita Albert Einstein /ID# 226640</name>
      <address>
        <city>São Paulo</city>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SHAT Hematologic Diseases /ID# 226007</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Sveta Marina /ID# 226681</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sociedad de Investigaciones Medicas /ID# 224175</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icegclinic /Id# 231086</name>
      <address>
        <city>La Florida</city>
        <state>Region Metropolitana Santiago</state>
        <zip>8241479</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez /ID# 225037</name>
      <address>
        <city>Providencia</city>
        <state>Region Metropolitana Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem /ID# 224085</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center /ID# 222151</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 223548</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital /ID# 228035</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital /ID# 228038</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital /ID# 225502</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Hospital /ID# 225503</name>
      <address>
        <city>Chuo-shi</city>
        <state>Yamanashi</state>
        <zip>409-3821</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital /ID# 233707</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic UZI 4D /ID# 229871</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol Skiy Kray</state>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre /ID# 227010</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon /ID# 233279</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orebro Universitetssjukhuset /ID# 228514</name>
      <address>
        <city>Orebro</city>
        <state>Orebro Lan</state>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset /ID# 228515</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala Lan</state>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 234215</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koc Universitesi Hastanesi Translasyonel Tıp Arastırma Merkezi /ID# 234214</name>
      <address>
        <city>Istanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABBV-744</keyword>
  <keyword>Navitoclax</keyword>
  <keyword>Ruxolitinib</keyword>
  <keyword>ABT-263</keyword>
  <keyword>Cancer</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>MF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

